Back to discover
Disease

Candidiasis, Vulvovaginal

Late-stage therapeutic developmentEmerging research
MeSHCandidiasis, Vulvovaginal
1
Publications
9
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones3View
Results expected 2
Recently completed 1
Activity timeline3

Clinical trials

8 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
9
All trials
3
Active
4
Late-stage
5
Completed
Late-stage studies

A Randomized Controlled Trial: the Effect of a Medical Grade Honey Formulation (L-Mesitran) on Clinical Symptoms of Recurrent Vulvovaginal Candidiasis

Phase 3 · Recruiting · Maastricht University Medical Center

Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo.

Phase 3 · Completed · Probionov

An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis

Phase 4 · Completed · Peking University Shenzhen Hospital

A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated

Phase 3 · Completed · Merck Sharp & Dohme LLC
Recently completed

A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)

Phase 2 · Completed · Matinas BioPharma Nanotechnologies, Inc.

A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis

Phase 2 · Completed · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo.

Phase 3 · Completed · Probionov

An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis

Phase 4 · Completed · Peking University Shenzhen Hospital

A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated

Phase 3 · Completed · Merck Sharp & Dohme LLC

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Zinc prevents vaginal candidiasis by inhibiting expression of an inflammatory fungal protein.

Science translational medicine · 2023 · 45 cites
Recent publications

Zinc prevents vaginal candidiasis by inhibiting expression of an inflammatory fungal protein.

Science translational medicine · 2023 · 45 cites
Major themes1
  • Candidiasis, Vulvovaginal1
Leading journals1
  • Science translational medicine1
Leading researchers8
  • Brown GD1
  • Comar M1
  • De Seta F1
  • Kozma B1
  • Nore A1
  • Pericolini E1
  • Roselletti E1
  • Sala A1
Affiliations (unnormalised)5
  • Eastern Virginia Medical School1
  • Institute for Maternal and Child Health-IRCCS1
  • Medical Research Council Centre for Medical Mycology at the University of Exeter1
  • University of Debrecen1
  • University of Modena and Reggio Emilia1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA.

Identifiers
MeSHCandidiasis, Vulvovaginal
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.